HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Endothelin receptor blockade does not affect blood pressure or angiotensin II levels in CYP1A1-Ren-2 transgenic rats with acutely induced hypertension.

Abstract
We found previously that selective blockade of endothelin ETA receptors is superior to nonselective ET(A)/ET(B) in attenuating hypertension and survival rate in Ren-2 transgenic rats (TGR). In the present pilot study, we were interested in whether similar effects will be found in TGR with inducible malignant hypertension (iTGR; official strain name Cyp1A1-Ren-2rats), which were derived from the original Ren-2 transgenic rat strain. Studies were performed in three-month old male iTGR. Treatment with either bosentan, a non-selective ET(A)/ET(B), or with atrasentan, a selective ET(A) receptor blocker, was started on day 2 of the experiment. Feeding with indole-3-carbinole (13C; 03% in rat chow), a natural xenobiotic which activates the Cyplal promoter of the mouse Ren-2 gene, began on day 3 and lasted for 4 days until day 6. Systolic BP, body weight, plasma ANG II and tissue ANG II and ET-1 concentrations were determined daily. Severe hypertension developed as early as 1 day after beginning of 13C feeding which was accompanied by a significant reduction in body weight and by increases in plasma and tissue ANG II and left ventricle ET-1 concentrations. Atrasentan or bosentan had no effects on the rise in BP or plasma and tissue ANG II concentrations but prevented the rise in heart ventricle ET-1 concentration. Our data show that blockade of the ET system does not prevent or attenuate the rapid development of severe hypertension in iTGR; a long-term protective effect of ET blockade on cardiac (and renal) damage, however, cannot be excluded and awaits further investigations.
AuthorsZdenka Vanourková, Herbert J Kramer, Michaela Erbanová, Angela Bäcker, Ludek Cervenka, Zuzana Husková, Vera Certíková Chábová, Vladimír Tesar, Pavel Dvorák, Jan Malý, Ivana Vanecková
JournalVascular pharmacology (Vascul Pharmacol) 2009 May-Jun Vol. 50 Issue 5-6 Pg. 194-9 ISSN: 1879-3649 [Electronic] United States
PMID19563737 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antihypertensive Agents
  • Endothelin Receptor Antagonists
  • Endothelin-1
  • Indoles
  • Pyrrolidines
  • Ren2 protein, rat
  • Sulfonamides
  • Angiotensin II
  • indole-3-carbinol
  • Cytochrome P-450 CYP1A1
  • Renin
  • Bosentan
  • Atrasentan
Topics
  • Angiotensin II (blood, metabolism)
  • Animals
  • Antihypertensive Agents (pharmacology)
  • Atrasentan
  • Blood Pressure (drug effects)
  • Bosentan
  • Cytochrome P-450 CYP1A1 (drug effects, genetics)
  • Disease Models, Animal
  • Endothelin Receptor Antagonists
  • Endothelin-1
  • Heart Ventricles (metabolism)
  • Hypertension (chemically induced, drug therapy)
  • Indoles (adverse effects)
  • Kidney (metabolism)
  • Male
  • Pyrrolidines (pharmacology)
  • Rats
  • Rats, Transgenic
  • Renin (genetics)
  • Sulfonamides (pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: